[New drugs, new therapeutic regimens, and new strategies for chemotherapy of stomatological cancers (author's transl)].
Two new drugs have been proved to be effective for isolated or recurrent stomatological tumors : detorubicine (limited because of cardiotoxicity), and CDDP (limited because of renal and neurological toxicity). Drugs used mainly as adjuvant treatment concurrently with BCG, as immunotherapy, are bestatine (without clinical or biological toxicity) and levamisole (rare cases of agranulocytosis). Randomized trials of chemo- and immunotherapy now underway are the only means of assessing long-term efficacy of adjuvant treatments.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D009062:Mouth Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001761:Bleomycin; D004317:Doxorubicin; D002945:Cisplatin
Nouvelles drogues, nouveaux protocoles, nouvelles stratégies en chimiothérapie des cancers stomatologiques.